Kyle C. Molina

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty et al. · The Lancet Infectious Diseases · 2023 · 138 citations · Full text

Retrospective Cohort Study, Covid-19 Pandemic, Real-world Use +8

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>

Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette et al. · Open Forum Infectious Diseases · 2021 · 51 citations · Full text

Early Experience With Eravacycline for Complicated Infections

Sara Alosaimy, Kyle C. Molina, Kimberly C. Claeys et al. · Open Forum Infectious Diseases · 2020 · 46 citations · Full text

Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care

Tanner M Johnson, Kyle C. Molina, Matthew A. Miller et al. · International Journal of Antimicrobial Agents · 2021 · 44 citations

Antimicrobial Susceptibility, Health Sciences, Healthcare-associated Infection +8

Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents

Matthew A. Miller, Kyle C. Molina, Jonathan A. Gutman et al. · Open Forum Infectious Diseases · 2020 · 42 citations · Full text